Ksaliproden

Ksaliproden
(IUPAC) ime
	1-[2-(2-naftil)etil]-4-[3-(trifluorometil)fenil]-1,2,3,6-tetrahidropiridin
Klinički podaci
Identifikatori
CAS broj	135354-02-8
ATC kod	N07XX03
PubChem	128919
ChemSpider	114237
UNII	V8QL94KNQO
KEGG	D06327
Hemijski podaci
Formula	C24H22F3N
Mol. masa	381,433 g/mol
InChI
	InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2 ; Key: WJJYZXPHLSLMGE-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Ksaliproden (SR57746) je lek koji deluje kao 5HT_1A agonist.^[5] On ima neurotrofno i neuroprotektivno dejstvo in vitro,^[6]^[7] i predložen je kao potencijalni tretman za nekoliko neurodegenerativnih oboljenja, među kojima su amiotrofična lateralna skleroza (ALS)^[8] i Alchajmerova bolest.^[9]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). „MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden”. International journal of immunopathology and pharmacology 18 (1): 21–31. PMID 15698508.
↑ Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). „Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology 127 (1): 139–44. DOI:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.
↑ Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). „Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology 128 (7): 1385–92. DOI:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.
↑ Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN i dr.. (2004). „Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 5 (2): 107–17. DOI:10.1080/14660820410019602. PMID 15204012.
↑ Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). „Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats”. Invest Radiol 37 (6): 321–7. DOI:10.1097/00004424-200206000-00003. PMID 12021588.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). „MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden”. International journal of immunopathology and pharmacology 18 (1): 21–31. PMID 15698508.

[6] Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). „Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology 127 (1): 139–44. DOI:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.

[7] Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). „Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology 128 (7): 1385–92. DOI:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.

[8] Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN i dr.. (2004). „Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 5 (2): 107–17. DOI:10.1080/14660820410019602. PMID 15204012.

[9] Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). „Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats”. Invest Radiol 37 (6): 321–7. DOI:10.1097/00004424-200206000-00003. PMID 12021588.

[5]

[6]

[7]

[8]

[9]

[1]

[2]

[3]

[4]